Genmab — December 2014
-
De har øget fra 0,59
-
331
-
-
Det er nok fordi at deres short i genmab er en del af et større short af sektoren, og ikke et direkte angreb på genmab. Derfor er de ret passive, og har kun shortet 0,6% af aktierne, da de angreb Vestas var de meget aktive, og forsvarede deres position, og havde shortet flere procent.
-
US banker ned. Genmab er fuldstændig ligeglad
-
Smuk tanke Solsen https://www.youtube.com/watch?v=3vDWWy4CMhE
-
http://ecancer.org/conference/534-ash-2014/video/3374/best-of-ash-2014.php En gennemgang af de bedste nyheder på ash. Både Dara og Ofa nævnt. Godt gået Genmab !
-
Læser lidt op på ASH på MB og dette fik mig til at smile: "The audience at the session responded well to Dr. Plesner’s presentation. The results he presented appeared to be further evidence that daratumumab is highly active and safe as a myeloma therapy."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind